Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.
Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-Diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Polverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. Fragoulis GE, et al. Among authors: courvoisier ds. Ann Rheum Dis. 2023 Jun;82(6):742-753. doi: 10.1136/ard-2022-223335. Epub 2022 Nov 3. Ann Rheum Dis. 2023. PMID: 36328476
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ. Gabay C, et al. Among authors: courvoisier ds. Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22. Ann Rheum Dis. 2018. PMID: 29472362 Free PMC article. Clinical Trial.
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C. Lauper K, et al. Among authors: courvoisier ds. Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5. Ann Rheum Dis. 2018. PMID: 29730637
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, Gottenberg JE, Bergstra SA, Suarez MP, Codreanu C, Kvien TK, Santos MJ, Pavelka K, Hetland ML, Askling J, Turesson C, Kubo S, Tanaka Y, Iannone F, Choquette D, Nordström DC, Rotar Z, Lukina G, Gabay C, Van Vollenhoven R, Finckh A. Courvoisier DS, et al. Rheumatology (Oxford). 2021 Feb 1;60(2):820-828. doi: 10.1093/rheumatology/keaa393. Rheumatology (Oxford). 2021. PMID: 32810263
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology.
Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Landewé RB, Finckh A, Bergstra SA, Courvoisier DS. Lauper K, et al. Among authors: courvoisier ds. RMD Open. 2021 Nov;7(3):e001818. doi: 10.1136/rmdopen-2021-001818. RMD Open. 2021. PMID: 34789534 Free PMC article.
221 results